[Recording available] Immune checkpoint inhibitors and beyond | Dr. Hiroyoshi NIishikawa - Prof. Daniel Olive
2022-01-13 | 09:00 AM - 11:00 AM (GMT+01:00) Paris
Information
09:00 AM - 11:00 AM CET
17:00 PM - 19:00 PM JST
Hiroyoshi Nishikawa, M.D., Ph.D.
Division of Cancer Immunology
Research Institute/EPOC
National Cancer Center of Japan
Immunosuppression in the tumor microenvironment
The fields of immunology and oncology are now being linked, and cancer immunotherapy, particularly immune checkpoint blockade (ICB) resurges effector T cells and provides clinical efficacy in various types of cancer. However, more than half of patients treated with ICB therapy fail to respond, even in combination, uncovering a limited window of the clinical responses. Thus, it is necessary to develop more effective cancer immunotherapeutic strategies and define biomarkers for stratifying responders and non-responders through the detailed analysis of immune responses in patients. In this webinar, I will discuss integrated analyses of immunological and genomic assays to understand comprehensive immune suppressive network in the tumor microenvironment.
Daniel Olive, M.D., Ph.D.
Laboratoire d'Immunologie des Tumeurs
IBiSA Cancer Immunomonitoring Platform
Centre de Recherche en Cancérologie de Marseille, CRCM
Inserm UMR1068, CNRS UMR7258, Aix Marseille Université U105, Institut Paoli Calmettes
Co-signaling molecules - Is there a place for other co-signaling molecules in addition to anti-PD-1 and anti-PD-L1?
The PD1-PDL1 axis is now a benchmark in the treatment in some solid tumors including neo-adjuvant therapies. Whereas there is an increasing use of combination therapies using anti-CTLA-4, we will present some of the novel co-signaling molecules that are important and are either used in Phase-1 clinical trials or preclinical stage. The presentation will mainly focus on the butyrophylin family members and their role in innate immunity. We will also tackle the role of the ICOS molecule and its role in the immunotherapy of lymphomas.
